Trimedyne Inc. of Lake Forest, Calif., has announced that it has received US Patent No. 7,492,987 covering an improvement in side-firing laser fibers that increases their tissue vaporization rate and durability. The fiber will be marketed by Boston Scientific Corp. in the US and Japan and by Lumenis Ltd. of Yokneam, Israel, a manufacturer of medical lasers. Marketing is expected to begin when Boston Scientific completes its audit of Trimedyne’s manufacturing facility and quality system. The fiber will be sold for use with Lumenis’ holmium lasers in the treatment of benign prostatic hyperplasia, an enlarged prostate that affects about 50 percent of men over the age of 55.